Gryphon Bio develops blood tests that utilize biomarkers from brain-specific molecules to monitor brain health and detect diseases such as traumatic brain injury and Alzheimer's. These tests provide critical data for healthcare providers to make informed decisions regarding patient recovery and treatment pathways.
Funding
$650K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Diagnosing and monitoring brain health currently relies on subjective assessments and expensive, often inaccessible, imaging techniques. This lack of objective, easily accessible tools hinders timely intervention and personalized treatment for various neurological conditions.
Solution
Gryphon Bio is developing a suite of blood tests that quantify brain-specific biomarkers to objectively assess and monitor brain health. These tests leverage the discovery that levels of brain molecules in the blood change in response to various neurological conditions, providing a dynamic snapshot of brain health. By measuring these biomarkers, Gryphon Bio's tests aim to provide clinicians with critical data to inform decisions regarding patient recovery, hospitalization, and treatment pathways. The blood tests can also be used in conjunction with drug development to track patient response and accelerate clinical trials.
Target Audience
The primary target audience includes healthcare providers, such as neurologists and emergency medicine physicians, who need objective tools to assess and monitor brain health, as well as pharmaceutical companies conducting clinical trials for neurological disorders.
Features
- Measures thousands of brain-specific molecules in the blood to identify biomarkers of brain health.
- Developing blood tests for traumatic brain injury (TBI), Alzheimer's disease (AD), post-traumatic epilepsy (PTE), and other neurological conditions.
- Designed to provide objective data for assessing brain health and monitoring disease progression.
- Aims to improve clinical decision-making regarding patient recovery and treatment.
- Can be used to enrich and track patients responding to various drugs in clinical trials.